Analyst Rating Update on Insulet Corporation (PODD)

Insulet Corporation (PODD) : Zacks Investment Research ranks Insulet Corporation (PODD) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 16 research analysts is 1.94, which indicates as a Buy.

Insulet Corporation (PODD) : The consensus price target for Insulet Corporation (PODD) is $38.66 for the short term with a standard deviation of $3.09. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $44, however, the pessimist price target for the company is $34.

For the current week, the company shares have a recommendation consensus of Buy.


Insulet Corporation (NASDAQ:PODD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.15 and $33.33 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $36.31. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.45, notching a gain of 0.42% for the day. The total traded volume was 873,866 . The stock had closed at $35.30 on the previous day.

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.